Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
Kishimoto TK, Fournier M, Michaud A, Rizzo G, Roy C, Capela T, Nukolova N, Li N, Doyle L, Fu FN, VanDyke D, Traber PG, Spangler JB, Leung SS, Ilyinskii PO. Kishimoto TK, et al. J Autoimmun. 2023 Oct 14;140:103125. doi: 10.1016/j.jaut.2023.103125. Online ahead of print. J Autoimmun. 2023. PMID: 37844543 Free article.
Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
Ilyinskii PO, Roy CJ, O'Neil CP, Browning EA, Pittet LA, Altreuter DH, Alexis F, Tonti E, Shi J, Basto PA, Iannacone M, Radovic-Moreno AF, Langer RS, Farokhzad OC, von Andrian UH, Johnston LP, Kishimoto TK. Ilyinskii PO, et al. Among authors: kishimoto tk. Vaccine. 2014 May 19;32(24):2882-95. doi: 10.1016/j.vaccine.2014.02.027. Epub 2014 Mar 1. Vaccine. 2014. PMID: 24593999 Free PMC article.
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.
Kishimoto TK, Ferrari JD, LaMothe RA, Kolte PN, Griset AP, O'Neil C, Chan V, Browning E, Chalishazar A, Kuhlman W, Fu FN, Viseux N, Altreuter DH, Johnston L, Maldonado RA. Kishimoto TK, et al. Nat Nanotechnol. 2016 Oct;11(10):890-899. doi: 10.1038/nnano.2016.135. Epub 2016 Aug 1. Nat Nanotechnol. 2016. PMID: 27479756
Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis.
LaMothe RA, Kolte PN, Vo T, Ferrari JD, Gelsinger TC, Wong J, Chan VT, Ahmed S, Srinivasan A, Deitemeyer P, Maldonado RA, Kishimoto TK. LaMothe RA, et al. Among authors: kishimoto tk. Front Immunol. 2018 Mar 2;9:281. doi: 10.3389/fimmu.2018.00281. eCollection 2018. Front Immunol. 2018. PMID: 29552007 Free PMC article.
Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.
Meliani A, Boisgerault F, Hardet R, Marmier S, Collaud F, Ronzitti G, Leborgne C, Costa Verdera H, Simon Sola M, Charles S, Vignaud A, van Wittenberghe L, Manni G, Christophe O, Fallarino F, Roy C, Michaud A, Ilyinskii P, Kishimoto TK, Mingozzi F. Meliani A, et al. Among authors: kishimoto tk. Nat Commun. 2018 Oct 5;9(1):4098. doi: 10.1038/s41467-018-06621-3. Nat Commun. 2018. PMID: 30291246 Free PMC article.
Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector.
De Sabbata G, Boisgerault F, Guarnaccia C, Iaconcig A, Bortolussi G, Collaud F, Ronzitti G, Sola MS, Vidal P, Rouillon J, Charles S, Nicastro E, D'Antiga L, Ilyinskii P, Mingozzi F, Kishimoto TK, Muro AF. De Sabbata G, et al. Among authors: kishimoto tk. Mol Ther Methods Clin Dev. 2020 Nov 17;20:169-180. doi: 10.1016/j.omtm.2020.11.005. eCollection 2021 Mar 12. Mol Ther Methods Clin Dev. 2020. PMID: 33473356 Free PMC article.
86 results